ELMS STEVE 4
4 · ADMA BIOLOGICS, INC. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
ADMA Director Steve Elms Buys 14,000 Shares in Open Market
What Happened Steve Elms, a director of ADMA Biologics, bought a total of 14,000 shares of ADMA common stock in open-market transactions — 7,000 shares on March 5, 2026 at a weighted average price of $15.67 ($109,690) and 7,000 shares on March 6, 2026 at a weighted average price of $15.39 ($107,730). The combined cash outlay for both purchases was approximately $217,420. These were purchases (insider buys), not sales or option exercises.
Key Details
- Transaction dates and prices:
- Mar 5, 2026 — 7,000 shares, weighted avg $15.67 (individual trade prices ranged $15.58–$15.74) — $109,690 (Footnote F1).
- Mar 6, 2026 — 7,000 shares, weighted avg $15.39 (individual trade prices ranged $15.35–$15.42) — $107,730 (Footnote F4).
- Total shares acquired: 14,000; total value ≈ $217,420.
- Reported holdings after transaction (per filing footnotes): 2,031,730 shares held by Aisling Capital II LP, 14,000 shares held by Aisling Arcturus Partners (the 14,000 include these purchases), plus 87,330 shares reported as owned by Mr. Elms personally. The filing also notes 10,690 restricted stock units (vest Feb 9, 2027) (Footnotes F3, F5).
- Disclosure notes: Mr. Elms is a designee of Aisling Capital and may be deemed to beneficially own shares held by Aisling entities but disclaims beneficial ownership except to the extent of any pecuniary interest (Footnote F3).
- Additional procedural note: The filing includes a commitment to provide a detailed breakdown of trades within the reported price ranges upon request (Footnote F2).
- Timeliness: Form 4 was filed on Mar 9, 2026 for transactions on Mar 5–6, 2026 — the filing appears timely under the 2-business-day rule.
Context These were straightforward open-market purchases (transaction code P) rather than exercises, awards, or gifts. Purchases by directors can be of interest to investors as one data point about insider buying activity, but they should be considered alongside other information (company fundamentals, institutional holdings, and broader market activity). The filing clarifies the mix of personal and fund-held shares and includes unvested RSUs that vest in 2027.
Insider Transaction Report
- Purchase
Common Stock
[F1][F2][F3]2026-03-05$15.67/sh+7,000$109,690→ 2,038,730 total(indirect: See footnote) - Purchase
Common Stock
[F2][F4][F3]2026-03-06$15.39/sh+7,000$107,730→ 2,045,730 total(indirect: See footnote)
- 98,020
Common Stock
[F5]
Footnotes (5)
- [F1]The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the "Issuer") common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive.
- [F2]The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.
- [F3]Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.
- [F4]The reported transaction reflects the open market purchase of shares of the Issuer's common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.35 to $15.42, inclusive.
- [F5]Includes, as of the transaction date, (i) 10,690 restricted stock units granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 87,330 shares of common stock owned by the Reporting Person.